Symphogen A/S - Product Pipeline Review - 2016

Date: December 21, 2016
Pages: 38
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until March 31, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S09BD8032E9EN
Leaflet:

Download PDF Leaflet

Symphogen A/S - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Symphogen A/S - Product Pipeline Review - 2016’, provides an overview of the Symphogen A/S’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Symphogen A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of Symphogen A/S
  • The report provides overview of Symphogen A/S including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Symphogen A/S’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Symphogen A/S’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Symphogen A/S’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Symphogen A/S
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Symphogen A/S’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Symphogen A/S Snapshot
Symphogen A/S Overview
Key Facts
Symphogen A/S - Research and Development Overview
Key Therapeutic Areas
Symphogen A/S - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Symphogen A/S - Pipeline Products Glance
Symphogen A/S - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Symphogen A/S - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Symphogen A/S - Drug Profiles
futuximab + modotuximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TIM-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sym-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYM-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Symphogen A/S - Pipeline Analysis
Symphogen A/S - Pipeline Products by Target
Symphogen A/S - Pipeline Products by Route of Administration
Symphogen A/S - Pipeline Products by Molecule Type
Symphogen A/S - Pipeline Products by Mechanism of Action
Symphogen A/S - Dormant Projects
Symphogen A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
rozrolimupab
Symphogen A/S - Company Statement
Symphogen A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Symphogen A/S, Key Facts
Symphogen A/S - Pipeline by Indication, 2016
Symphogen A/S - Pipeline by Stage of Development, 2016
Symphogen A/S - Monotherapy Products in Pipeline, 2016
Symphogen A/S - Combination Treatment Modalities in Pipeline, 2016
Symphogen A/S - Phase II, 2016
Symphogen A/S - Phase I, 2016
Symphogen A/S - Preclinical, 2016
Symphogen A/S - Discovery, 2016
Symphogen A/S - Pipeline by Target, 2016
Symphogen A/S - Pipeline by Route of Administration, 2016
Symphogen A/S - Pipeline by Molecule Type, 2016
Symphogen A/S - Pipeline Products by Mechanism of Action, 2016
Symphogen A/S - Dormant Developmental Projects,2016
Symphogen A/S - Discontinued Pipeline Products, 2016
Symphogen A/S, Subsidiaries

LIST OF FIGURES

Symphogen A/S - Pipeline by Top 10 Indication, 2016
Symphogen A/S - Pipeline by Stage of Development, 2016
Symphogen A/S - Monotherapy Products in Pipeline, 2016
Symphogen A/S - Combination Treatment Modalities in Pipeline, 2016
Symphogen A/S - Pipeline by Target, 2016
Symphogen A/S - Pipeline by Route of Administration, 2016
Symphogen A/S - Pipeline by Molecule Type, 2016
Symphogen A/S - Pipeline Products by Mechanism of Action, 2016
Skip to top


Ask Your Question

Symphogen A/S - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: